Randomised clinical trial of interferon rebound therapy for chronic hepatitisB patients
Not Applicable
Recruiting
- Conditions
- chronic hepatitis B
- Registration Number
- JPRN-UMIN000009159
- Lead Sponsor
- Toranomon Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Cirrhosis or hepatic failure such as chronic liver diseases, e.g. autoimmune hepatitis and alcoholic hepatitis (2)History of pneumonitis (3) Severe other diseases (4)Severe mental disorders (5)Pregnant woman or woman who has possibility of pregnancy or woman while suckling (6)Doctor judged patient as inappropriate person in this trial
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HBe seroconversion and the suppression of HBV DNA levels to below 5.0Log copies/ml and the normalization of alanine aminotransferase levels at 24 weeks treatment of interferon therapy or Nucleoside analogue therapy
- Secondary Outcome Measures
Name Time Method HBe seroconversion and undetectable HBV DNA and normalization of alanine aminotransferase levels and negative HBeAg and negative HBsAg and HBs seroconversion and HBsAg and HBcrAg